Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

MiR-942 mediates hepatitis C virus-induced apoptosis via regulation of ISG12a.

Yang D, Meng X, Xue B, Liu N, Wang X, Zhu H.

PLoS One. 2014 Apr 11;9(4):e94501. doi: 10.1371/journal.pone.0094501. eCollection 2014.

2.

Innate host response in primary human hepatocytes with hepatitis C virus infection.

Yang D, Liu N, Zuo C, Lei S, Wu X, Zhou F, Liu C, Zhu H.

PLoS One. 2011;6(11):e27552. doi: 10.1371/journal.pone.0027552. Epub 2011 Nov 8.

3.

ISG12a inhibits HCV replication and potentiates the anti-HCV activity of IFN-α through activation of the Jak/STAT signaling pathway independent of autophagy and apoptosis.

Chen Y, Jiao B, Yao M, Shi X, Zheng Z, Li S, Chen L.

Virus Res. 2017 Jan 2;227:231-239. doi: 10.1016/j.virusres.2016.10.013. Epub 2016 Oct 21.

PMID:
27777077
4.

miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT.

Liu N, Zuo C, Wang X, Chen T, Yang D, Wang J, Zhu H.

Oncotarget. 2014 Jul 15;5(13):4959-71.

5.

Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.

Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford JM, Nelson DR, Liu C.

Gastroenterology. 2007 Nov;133(5):1649-59. Epub 2007 Sep 16.

PMID:
17983809
6.

Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway.

Mukherjee A, Di Bisceglie AM, Ray RB.

J Virol. 2015 Mar;89(6):3356-65. doi: 10.1128/JVI.03085-14. Epub 2015 Jan 14.

7.

EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway.

Zhu C, Xiao F, Hong J, Wang K, Liu X, Cai D, Fusco DN, Zhao L, Jeong SW, Brisac C, Chusri P, Schaefer EA, Zhao H, Peng LF, Lin W, Chung RT.

J Virol. 2015 Jul;89(13):6608-18. doi: 10.1128/JVI.00364-15. Epub 2015 Apr 15.

8.

Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes.

Wang Y, Ye L, Wang X, Li J, Song L, Ho W.

Innate Immun. 2013;19(2):193-202. doi: 10.1177/1753425912460414. Epub 2012 Oct 11.

9.

Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.

Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD.

Antimicrob Agents Chemother. 2013 Sep;57(9):4417-26. doi: 10.1128/AAC.00399-13. Epub 2013 Jul 8.

10.

ISG12a Restricts Hepatitis C Virus Infection through the Ubiquitination-Dependent Degradation Pathway.

Xue B, Yang D, Wang J, Xu Y, Wang X, Qin Y, Tian R, Chen S, Xie Q, Liu N, Zhu H.

J Virol. 2016 Jul 11;90(15):6832-45. doi: 10.1128/JVI.00352-16. Print 2016 Aug 1.

11.

DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture.

Grünvogel O, Esser-Nobis K, Reustle A, Schult P, Müller B, Metz P, Trippler M, Windisch MP, Frese M, Binder M, Fackler O, Bartenschlager R, Ruggieri A, Lohmann V.

J Virol. 2015 Oct;89(20):10548-68. doi: 10.1128/JVI.01297-15. Epub 2015 Aug 12.

12.

Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells.

Eksioglu EA, Zhu H, Bayouth L, Bess J, Liu HY, Nelson DR, Liu C.

PLoS One. 2011;6(6):e21186. doi: 10.1371/journal.pone.0021186. Epub 2011 Jun 17.

13.

Hepatitis C Virus Nonstructural 5A Protein (HCV-NS5A) Inhibits Hepatocyte Apoptosis through the NF-κb/miR-503/bcl-2 Pathway.

Xie Z, Xiao Z, Wang F.

Mol Cells. 2017 Mar;40(3):202-210. doi: 10.14348/molcells.2017.2299. Epub 2017 Mar 27.

14.

Contradicting roles of miR-182 in both NK cells and their host target hepatocytes in HCV.

El Sobky SA, El-Ekiaby NM, Mekky RY, Elemam NM, Mohey Eldin MA, El-Sayed M, Esmat G, Abdelaziz AI.

Immunol Lett. 2016 Jan;169:52-60. doi: 10.1016/j.imlet.2015.10.013. Epub 2015 Oct 27.

PMID:
26518141
15.

MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway.

Duan X, Li S, Holmes JA, Tu Z, Li Y, Cai D, Liu X, Li W, Yang C, Jiao B, Schaefer EA, Fusco DN, Salloum S, Chen L, Lin W, Chung RT.

J Virol. 2018 Mar 14;92(7). pii: e02009-17. doi: 10.1128/JVI.02009-17. Print 2018 Apr 1.

16.

Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection.

Brownell J, Bruckner J, Wagoner J, Thomas E, Loo YM, Gale M Jr, Liang TJ, Polyak SJ.

J Virol. 2014 Feb;88(3):1582-90. doi: 10.1128/JVI.02007-13. Epub 2013 Nov 20.

17.

Transcriptional regulation of IFN-λ genes in hepatitis C virus-infected hepatocytes via IRF-3·IRF-7·NF-κB complex.

Lee HC, Narayanan S, Park SJ, Seong SY, Hahn YS.

J Biol Chem. 2014 Feb 21;289(8):5310-9. doi: 10.1074/jbc.M113.536102. Epub 2014 Jan 2. Erratum in: J Biol Chem. 2014 Apr 25;289(17):11861.

18.

Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells.

Yao L, Yan X, Dong H, Nelson DR, Liu C, Li X.

Virol J. 2011 Sep 21;8:445. doi: 10.1186/1743-422X-8-445.

19.

Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1.

He CL, Liu M, Tan ZX, Hu YJ, Zhang QY, Kuang XM, Kong WL, Mao Q.

World J Gastroenterol. 2018 Jan 14;24(2):226-236. doi: 10.3748/wjg.v24.i2.226.

20.

HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection.

Israelow B, Narbus CM, Sourisseau M, Evans MJ.

Hepatology. 2014 Oct;60(4):1170-9. doi: 10.1002/hep.27227. Epub 2014 Aug 21.

Supplemental Content

Support Center